News | February 24, 2026
Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
Inspection included drug device combinations covering our recent filing in nasal sprays domain
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Granules India has reported total income of Rs. 1,384.29 crore during the period ended December 31, 2025
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
